使用疟涤平（乙胺嘧啶和氨苯砜）预防疟疾期间出现的粒细胞缺乏症。
Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone).
作者信息
Booth F, Barker L C, Barton C J, Naik R B
出版信息
Postgrad Med J. 1984 Aug;60(706):566-7. doi: 10.1136/pgmj.60.706.566.
Abstract
A case of agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone) is described. At the recommended dose of one tablet weekly this is apparently a rare occurrence but highlights one of the hazards in a changing climate of malarial prophylaxis in which the use of Maloprim is increasing.
摘要
描述了一例在使用疟涤平（乙胺嘧啶和氨苯砜）预防疟疾期间发生粒细胞缺乏症的病例。按照每周一片的推荐剂量，这种情况显然很少见，但凸显了在疟疾预防环境不断变化、疟涤平使用日益增加的情况下的一种风险。
相似文献
1
Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone).使用疟涤平（乙胺嘧啶和氨苯砜）预防疟疾期间出现的粒细胞缺乏症。
Postgrad Med J. 1984 Aug;60(706):566-7. doi: 10.1136/pgmj.60.706.566.
2
Agranulocytosis associated with malaria prophylaxis with Maloprim.与使用疟涤平预防疟疾相关的粒细胞缺乏症。
Br Med J (Clin Res Ed). 1983 Apr 16;286(6373):1244-5. doi: 10.1136/bmj.286.6373.1244.
3
Agranulocytosis associated with maloprim: review of cases.
Hum Toxicol. 1986 Jul;5(4):221-7. doi: 10.1177/096032718600500402.
4
Agranulocytosis associated with Maloprim.与疟乃停相关的粒细胞缺乏症。
Br Med J (Clin Res Ed). 1984 Jan 7;288(6410):65-6. doi: 10.1136/bmj.288.6410.65-d.
5
Maloprim and agranulocytosis.疟涤平与粒细胞缺乏症
Lancet. 1983;2(8365-66):1487-8. doi: 10.1016/s0140-6736(83)90825-5.
6
Agranulocytosis associated with Maloprim.与疟涤平相关的粒细胞缺乏症。
Br Med J (Clin Res Ed). 1983 May 7;286(6376):1515. doi: 10.1136/bmj.286.6376.1515.
7
Maloprim for malaria prophylaxis.用于疟疾预防的疟涤平。
Med J Aust. 1985 Sep 30;143(7):319-20. doi: 10.5694/j.1326-5377.1985.tb123035.x.
8
Chemoprophylaxis of malaria in Africa.非洲疟疾的化学预防
Br Med J (Clin Res Ed). 1983 Feb 12;286(6364):562.
9
Maloprim--general toxicity or idiosyncrasy?疟涤平——是一般毒性还是特异反应？
P N G Med J. 1984 Mar;27(1):46.
10
Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine.
Med J Aust. 1985 Aug 19;143(4):139-41. doi: 10.5694/j.1326-5377.1985.tb122869.x.
引用本文的文献
1
Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs.确定与化学预防抗疟药物相关的严重不良反应风险。
Bull World Health Organ. 1990;68(4):493-504.
本文引用的文献
1
Chemoprophylaxis of malaria in Africa: the spent "magic bullet".非洲疟疾的化学预防：失效的“神奇子弹”
Br Med J (Clin Res Ed). 1982 Sep 11;285(6343):674-6. doi: 10.1136/bmj.285.6343.674.
2
Agranulocytosis associated with malaria prophylaxis with Maloprim.与使用疟涤平预防疟疾相关的粒细胞缺乏症。
Br Med J (Clin Res Ed). 1983 Apr 16;286(6373):1244-5. doi: 10.1136/bmj.286.6373.1244.
3
Chemoprophylaxis of malaria in Africa.非洲疟疾的化学预防
Br Med J (Clin Res Ed). 1983 Feb 12;286(6364):562.
4
Presumptive fatality due to pyrimethamine-sulfadoxine.推定因乙胺嘧啶-磺胺多辛致死。
Lancet. 1982 Dec 4;2(8310):1272. doi: 10.1016/s0140-6736(82)90121-0.
5
Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine.使用乙胺嘧啶-磺胺多辛进行疟疾预防期间的严重反应。
Lancet. 1982 Oct 30;2(8305):994. doi: 10.1016/s0140-6736(82)90202-1.
Zotero 插件